Bal Pharma Limited (NSE:BALPHARMA)

Market Cap	1.61B
Revenue (ttm)	3.03B
Net Income (ttm)	72.15M
Shares Out	n/a
EPS (ttm)	4.56
PE Ratio	22.35
Forward PE	n/a
Dividend	1.20 (1.18%)
Ex-Dividend Date	Sep 17, 2024

Volume	11,736
Average Volume	29,120
Open	103.00
Previous Close	101.50
Day's Range	100.07 - 103.29
52-Week Range	78.06 - 157.98
Beta	0.20
RSI	54.28
Earnings Date	Aug 8, 2025

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 868
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BALPHARMA

Financial Performance

In 2024, Bal Pharma's revenue was 3.03 billion, a decrease of -10.65% compared to the previous year's 3.39 billion. Earnings were 72.15 million, a decrease of -2.39%.